Increased serum S100B protein in long-term antipsychotic medication chronic patients with schizophrenia

TAN Yun-Long,TAN Shu-Ping,CHEN Nan,HAN Biao,YANG Fu-De,CAO Lian-Yuan,LI Jia,ZHOU Dong-Feng,ZOU Yi-Zhuang
2010-01-01
Abstract:Objective:To investigate the correlation of the serum S100B protein levels with psychopathological symptoms in the long-term antipsychotic-medication chronic patients with schizophrenia.Methods:The serum S100B protein levels in 99 cases of the long-term antipsychotic-medication patients with chronic schizophrenia(schizophrenic group)and 83 healthy volunteers(control group)were examined by enzyme-linked immuno-sorbent assay(ELSIA).The serum S100B levels were compared between the schizophrenics and controls.Psychopathological symptoms were assessed with the Positive and Negative Symptom Scale(PANSS).The relationship of the serum S100B levels and the PANSS scores were analyzed in schizophrenic group.Results:(1)The serum S100B levels in schizophrenic group were significantly higher than that in control group [(0.158±0.037)μg/L vs.(0.124±0.055)μg/L,P<0.001].The serum S100B levels in male patients were markedly higher than that in females [(0.169±0.035)μg/L vs.(0.136±0.030)μg/L,P<0.001],but significant differences were not found among antipsychotic-medication subgroups(F=1.22,P=0.307).(2)The serum S100B levels were significantly correlated with negative sub-score(r=-0.31,P=0.002)and response deficiency factor(r=-0.24,P=0.017)of the PANSS.Conclusion:The serum S100B protein levels increase and may provide potential protecting for development of disease in long-term antipsychotic-medication chronic patients with schizophrenia.
What problem does this paper attempt to address?